本文選題：中東呼吸綜合征 + 中東呼吸綜合征冠狀病毒��； 參考：《國(guó)際藥學(xué)研究雜志》2015年03期

【摘要】：中東呼吸綜合征(MERS)是由新型冠狀病毒MERS-CoV感染引起的傳染病,2012年在沙特被首次發(fā)現(xiàn),疫情主要集中在中東地區(qū),在歐洲、非洲、北美洲和亞洲也有少量病例報(bào)告,近期韓國(guó)連續(xù)報(bào)告數(shù)十病例,并且1例經(jīng)香港輸入中國(guó)大陸地區(qū)。目前,臨床上尚無(wú)針對(duì)MERS-CoV的特異性抗病毒藥物和治療方法,主要是對(duì)癥治療,在防止并發(fā)癥的同時(shí)實(shí)施有效的呼吸、循環(huán)支持和腎功能保護(hù)。本文對(duì)文獻(xiàn)報(bào)道的潛在臨床治療方法,抗MERS-CoV的潛在藥物靶點(diǎn)和小分子治療藥物的研究進(jìn)展進(jìn)行綜述。
[Abstract]:MERS, an infectious disease caused by a new type of coronavirus MERS-CoV infection, was first discovered in Saudi Arabia in 2012. The epidemic is concentrated in the Middle East, with a small number of cases reported in Europe, Africa, North America and Asia. Dozens of cases have been reported in South Korea recently, and one case has been imported into mainland China via Hong Kong. At present, there are no specific antiviral drugs and treatments for MERS-CoV, mainly for symptomatic treatment, which can prevent complications while implementing effective respiratory, circulatory support and renal function protection. In this review, the potential clinical treatment methods, potential drug targets of anti-MERS-CoV and the research progress of small molecular therapy drugs reported in the literature were reviewed.
【作者單位】： 國(guó)家應(yīng)急防控藥物工程技術(shù)研究中心 軍事醫(yī)學(xué)科學(xué)院毒物藥物研究所;
【基金】：國(guó)家重大新藥創(chuàng)制科技重大專項(xiàng)資助項(xiàng)目專項(xiàng)(2014ZX09304-001)
【分類號(hào)】：R511

【共引文獻(xiàn)】

相關(guān)期刊論文 前8條

1 吳家兵;黃永;龔磊;;中東呼吸綜合征流行病學(xué)研究進(jìn)展[J];安徽預(yù)防醫(yī)學(xué)雜志;2014年04期

2 王國(guó)慶;朱紫祥;曹偉軍;劉磊;鄭海學(xué);;RNA病毒阻斷RIG-I樣受體識(shí)別dsRNA機(jī)制研究進(jìn)展[J];病毒學(xué)報(bào);2014年06期

3 王，

本文編號(hào)：1934466